hereditary hemochromatosis iron overload disease
Conditions
Interventions
After an overnight fast serum iron and hepcidin concentration will be
determined. Healthy controls and hemochromatosis patients will then receive
iron (Fe3+) polymaltose containing 50 mg of iron, th
Sponsors
Medisch Universitair Ziekenhuis Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a hemochromatosis patient must meet all of the following criteria: • Patients with hereditary hemochromatosis, homozygous for C282Y, with biochemical or liver biopsy proven iron overload in the past. • Patients are currently on maintenance treatment of which the last treatment was more than six weeks ago. • Ferritin levels for men and postmenopausal women should be 18 years, 18,
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: • Patients/subjects with known acute or chronic inflammatory disorders, such as inflammatory bowel disease or rheumatoid arthritis, hepatitis B, hepatitis C or HIV infection • Patients/subjects with cirrhosis of the liver • Patients/subjects with excess alcohol ingestion (> 21 glasses a week for men, >14 glasses a week for women) • Phlebotomy/erythrocytapharesis less than 6 weeks before participation in research • Patients/subjects 65 years • Patients/subjects with a malignancy • Patients/subject who are anemic • Patients/subjects already on PPI treatment • Patients/subjects who experienced side effects of PPI*s • Patients/subjects on different acid-suppressing medication (e.g. H2- blockers) • Patients/subjects that use iron supplements • Patients/subjects who are pregnant. • Patients/subjects who use medication that interferes with PPI medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The course in hepcidin concentration, measured after an oral iron challenge, before and after gastric acid suppression in hemochromatosis patients and healthy controls will be the primary endpoint of the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoint is to prove the difference in increase of serum iron concentration, after oral iron challenge, before and after gastric acid suppression in hemochromatosis patients and healthy controls. | — |
Countries
Netherlands
Outcome results
None listed